Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer
Executive Summary
New England Journal of Medicine editorial sings the praises of CDK4/6 inhibitors in breast cancer, which include Pfizer's Ibrance, Novartis's ribociclib and Elli Lilly's abemaciclib.
You may also be interested in...
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
Novartis' Phase III MONALEESA-2 trial shows that ribociclib plus letrozole has strong efficacy and an acceptable tolerability profile for first-line advanced HR+/HER2- breast cancer patients, but analysts say the results do not surpass those of Pfizer's first-to-market Ibrance plus letrozole in a similar setting.